BR112018000253A2 - composto, composição, e, método para tratar a infecção pelo hiv. - Google Patents

composto, composição, e, método para tratar a infecção pelo hiv.

Info

Publication number
BR112018000253A2
BR112018000253A2 BR112018000253A BR112018000253A BR112018000253A2 BR 112018000253 A2 BR112018000253 A2 BR 112018000253A2 BR 112018000253 A BR112018000253 A BR 112018000253A BR 112018000253 A BR112018000253 A BR 112018000253A BR 112018000253 A2 BR112018000253 A2 BR 112018000253A2
Authority
BR
Brazil
Prior art keywords
compound
composition
hiv infection
treating hiv
compounds
Prior art date
Application number
BR112018000253A
Other languages
English (en)
Inventor
Narasimhulu Naidu B
F Kadow John
E Parcella Kyle
J Eastman Kyle
Patel Manoj
Tu Yong
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of BR112018000253A2 publication Critical patent/BR112018000253A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

são descritos compostos de fórmula i, incluindo sais farmaceuticamente aceitáveis, composições farmacêuticas que compreendem os compostos, métodos para preparar os compostos e o seu uso na inibição do hiv integrase e tratamento dos infectados com hiv ou aids.
BR112018000253A 2015-07-09 2016-07-07 composto, composição, e, método para tratar a infecção pelo hiv. BR112018000253A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190598P 2015-07-09 2015-07-09
PCT/IB2016/054089 WO2017006280A1 (en) 2015-07-09 2016-07-07 Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
BR112018000253A2 true BR112018000253A2 (pt) 2018-09-04

Family

ID=56373101

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000253A BR112018000253A2 (pt) 2015-07-09 2016-07-07 composto, composição, e, método para tratar a infecção pelo hiv.

Country Status (11)

Country Link
US (1) US20180147196A1 (pt)
EP (1) EP3319953A1 (pt)
JP (1) JP2018519349A (pt)
KR (1) KR20180025916A (pt)
CN (1) CN107771177A (pt)
AU (1) AU2016290205A1 (pt)
BR (1) BR112018000253A2 (pt)
CA (1) CA2991464A1 (pt)
IL (1) IL256450A (pt)
RU (1) RU2018103031A (pt)
WO (1) WO2017006280A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
TW201835068A (zh) * 2017-01-03 2018-10-01 英商Viiv醫療保健英國(No.5)有限公司 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2220095B1 (en) 2007-11-15 2013-01-02 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
JP5269086B2 (ja) 2007-11-15 2013-08-21 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスの複製阻害薬
UA100250C2 (uk) 2007-11-16 2012-12-10 Гілеад Сайнсіз, Інк. Інгібітори реплікації вірусу імунодефіциту людини
EP2220084B1 (en) 2007-11-16 2014-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
SG10201408512RA (en) 2009-12-23 2015-02-27 Univ Leuven Kath Novel antiviral compounds
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9580431B2 (en) 2013-03-13 2017-02-28 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2014159959A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
AU2016290205A1 (en) 2018-01-18
EP3319953A1 (en) 2018-05-16
US20180147196A1 (en) 2018-05-31
CN107771177A (zh) 2018-03-06
KR20180025916A (ko) 2018-03-09
JP2018519349A (ja) 2018-07-19
WO2017006280A1 (en) 2017-01-12
CA2991464A1 (en) 2017-01-12
IL256450A (en) 2018-02-28
RU2018103031A (ru) 2019-08-09

Similar Documents

Publication Publication Date Title
BR112018002689A2 (pt) composto, composição útil e método para tratamento de infecção por hiv
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112018077015A2 (pt) derivados de ácido borônico e usos terapêuticos dos mesmos
BR112017022544A2 (pt) ?composto, composição, e, método para tratamento de infecção por hiv?.
BR112017028504A2 (pt) derivados de sulfamoilarilamida ciclizada e uso dos mesmos como medicamentos para o tratamento da hepatite b
BR112018005904A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
BR112016006651A8 (pt) derivados de quinolizina substituídos, composição farmacêutica que os compreede e uso dos mesmos.
EA201790389A1 (ru) Пирролопиримидиновые соединения, используемые в качестве агониста tlr7
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
BR112015021027A2 (pt) compostos terapêuticos
EA201890425A1 (ru) Противовирусные фосфодиамидные сложноэфирные бета-аминокислотные соединения
BR112017011941A2 (pt) compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral
BR112018005870A2 (pt) composto, e, método de prevenção e/ou tratamento do hiv.
BR112018013251A2 (pt) compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase
BR112015007742B1 (pt) composto, composição farmacêutica, e, uso do referido composto
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
BR112017017500A2 (pt) derivado de quinolina para uso no tratamento e prevenção de infecções virais
BR112017028456A2 (pt) composto, e, método de prevenção e/ou tratamento de hiv
DOP2018000035A (es) Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112016016853A2 (pt) Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
BR112018006545A2 (pt) ?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
BR112019000453A2 (pt) combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]